Acquisitions (Rempex Pharmaceuticals, Inc.) (Details) (USD $)	1 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012
Estimated Purchase Price
Goodwill	$ 257,694,000	$ 286,532,000	$ 14,671,000
Rempex [Member]
Business Acquisition [Line Items]
Upfront cash consideration	140,000,000
Purchase price adjustments	300,000
Contingent consideration		315,700,000
Escrow fund		14,000,000
Acquisition related costs	2,600,000
Estimated Purchase Price
Upfront cash consideration	140,251,000
Fair value of contingent cash payment	96,700,000
Total purchase price	236,951,000
Cash and cash equivalents	4,218,000
Accounts receivable, net	399,000
Inventory	566,000
Prepaid expenses and other current assets	2,465,000
Fixed assets, net	331,000
In-process research and development	530,000
Goodwill	68,632,000
Total Assets	301,821,000
Accounts payable	1,413,000
Accrued expenses	5,867,000
Deferred tax liabilities	57,590,000
Total Liabilities	64,870,000
Total purchase price	236,951,000
In Process Research and Development [Member] | Rempex [Member]
Estimated Purchase Price
In-process research and development	224,680,000
Development and Regulatory Milestones [Member] | Rempex [Member]
Business Acquisition [Line Items]
Contingent consideration		214,000,000
Commercial Milestones [Member] | Rempex [Member]
Business Acquisition [Line Items]
Contingent consideration		$ 120,000,000